Clarus Therapeutics Holdings, Inc., recently announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, Jatenzo (testosterone undecanoate).
Related posts
-
Can Bulls do a rebuild the right way this time?
As the Bulls begin another roster rebuild, maybe they can avoid repeating the same old mistakes... -
After much debate, Gas N Wash plan clears hurdle in Wheeling
A plan to build a Gas N Wash station on Wheeling’s west side got preliminary approval... -
Amazon Fresh grocery store opening ‘very, very soon’ in Arlington Heights
At long last — after many starts and stops — the planned Amazon Fresh grocery store...